Taken together, these results demonstrate that the DNA tumor virus oncogenes LMP1 and HPV E7 sensitize NPC and cervical cancer cells to paclitaxel treatment through inhibition of PERK. This evidence concerns the gene EIF2AK3 and nasopharyngeal carcinoma.